With the aim to identify a therapeutic strategy for Huntington’s Disease (HD), we are developing different in vitro assays to screen small molecular weight compounds for their potency to inhibit aggregation and toxicity of mutant huntingtin protein in vitro. Efficacy of selected active compounds will then be tested in the HD mouse model R6/2 in collaboration with Gillian Bates (King’s College of London). Body weight, brain weight, biochemical methods as well as behavioral read-outs will be used to measure the protective effect of the compounds.